Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.
Cantor Fitzgerald analyst Prakhar Agrawal reiterates ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight.
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and lowers the price target from...
ORIC Pharmaceuticals (NASDAQ:ORIC) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of ...
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon ...
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinic...
JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and lowers the price target fro...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
HC Wainwright & Co. analyst Robert Burns maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price ta...
